Idelalisib
Idelalisib is a medication used to treat certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL) and follicular lymphoma. It works by inhibiting a specific enzyme called phosphoinositide 3-kinase (PI3K), which plays a crucial role in the survival and proliferation of cancer cells.
This drug is typically prescribed for patients who have not responded well to other treatments. It is taken orally and can help slow down the progression of the disease, improving the quality of life for those affected. However, it may also have side effects, including an increased risk of infections.